Enantioselective Effects of Hydroxy Metabolites of Bupropion on Behavior and on Function of Monoamine Transporters and Nicotinic Receptors

@article{Damaj2004EnantioselectiveEO,
  title={Enantioselective Effects of Hydroxy Metabolites of Bupropion on Behavior and on Function of Monoamine Transporters and Nicotinic Receptors},
  author={Mohamad Imad Damaj and F. Ivy Carroll and Jason Brek Eaton and Hern{\'a}n A. Navarro and Bruce E. Blough and Sadiq Mirza and Ronald J. Lukas and Billy R. Martin},
  journal={Molecular Pharmacology},
  year={2004},
  volume={66},
  pages={675 - 682}
}
Bupropion is an atypical antidepressant that also has usefulness as a smoking-cessation aid. Because hydroxybupropion, a major metabolite of bupropion, is believed to contribute to its antidepressant activity, this metabolite may also contribute to the smoking-cessation properties of bupropion. This study investigated the effects of hydrobupropion enantiomers on monoamine transporters and nicotinic acetylcholine receptor (nAChR) subtypes. Racemic bupropion and hydroxybupropion inhibit [3H… 

Tables from this paper

Effects of Hydroxymetabolites of Bupropion on Nicotine Dependence Behavior in Mice
TLDR
The hypothesis that the effects of buPropion on measures of nicotine dependence reflect actions of bupropion itself, its hydroxymetabolites, or a combination is supported and it is suggested that the (2S,3S)-hydroxy isomer is the most active principle, making it a potentially better drug candidate for smoking cessation than bu Propion.
Nicotinic acetylcholine receptor efficacy and pharmacological properties of 3-(substituted phenyl)-2β-substituted tropanes.
TLDR
Several new 3-phenyltropane analogues that are superior to 2 in inhibition of dopamine, norepinephrine, and sometimes serotonin reuptake are identified that have utility as research tools and possible promise for treatment of nicotine dependence.
Stereoselective Metabolism of Bupropion to OH-bupropion, Threohydrobupropion, Erythrohydrobupropion, and 4′-OH-bupropion in vitro
TLDR
The stereoselective pharmacokinetics and the effect of drug-drug interactions (DDIs) and CYP2C19 pharmacogenetics on bupropion exposure were quantitatively explained by the in vitro metabolic clearances and in vivo interconversion between buPropion stereoisomers.
Review of the pharmacology and clinical profile of bupropion, an antidepressant and tobacco use cessation agent.
TLDR
Clinically, bupropion is used as a treatment for two indications, as an antidepressant, the indication for which it was developed, and as a tobacco use cessation agent and is being tested as a candidate treatment for psychostimulant drug abuse, attention-deficit hyperactivity disorder (ADHD) and obesity.
Stereoselective disposition of bupropion and its three major metabolites : 4-hydroxybupropion, erythro-dihydrobupropion, and threo-dihydrobupropion
TLDR
A novel reversed phase chiral-HPLC-MS/MS method involving a simple liquid-liquid extraction procedure and a small plasma sample volume was developed that allowed simultaneous separation and quantification of enantiomers of bupropion, 4-hydroxybupropion, and those of threo- and erythro-dihydrob upropion in human plasma.
Interaction of nicotinic receptors with bupropion: Structural, functional, and pre-clinical perspectives
TLDR
There is emerging evidence that BP inhibits, in the low to intermediate micromolar range, various nicotinic acetylcholine receptors (AChRs) expressed in different neuronal pathways.
Stereoselective Glucuronidation of Bupropion Metabolites In Vitro and In Vivo
TLDR
These data systematically describe the metabolic pathways underlying bupropion metabolite disposition and significantly expand the knowledge of potential contributors to the interindividual and intraindividual variability in therapeutic and toxic effects of buPropion in humans.
Bupropion: pharmacology and therapeutic applications
TLDR
Anecdotal reports indicate bupropion may lower inflammatory mediators such as tumor necrosis factor-α, may lower fatigue in cancer and may help reduce concentration problems.
The Designer Methcathinone Analogs, Mephedrone and Methylone, are Substrates for Monoamine Transporters in Brain Tissue
TLDR
In vitro and in vivo methods demonstrate that designer methcathinone analogs are substrates for monoamine transporters, with a profile of transmitter-releasing activity comparable to MDMA.
Bupropion Inhibits Serotonin Type 3AB Heteromeric Channels at Clinically Relevant Concentrations
TLDR
It is demonstrated that bupropion inhibits heteromeric 5-HT3ABRs as well as homomeric 6-HT type 3AB receptors, and this inhibition occurs at clinically relevant concentrations and may contribute to bupropions clinical effects.
...
...

References

SHOWING 1-10 OF 42 REFERENCES
Behavioral and biochemical investigations of bupropion metabolites.
Antidepressant profile of bupropion and three metabolites in mice.
TLDR
Bupropion has a pharmacological spectrum in various animal models which predicts both antidepressant and stimulatory activity in man, and data suggest that the clinical antidepressant profile observed in man after administration of buPropion is related to metabolite BW 306 and possibly to BW 494, rather than to bupropion itself.
Evidence that the Acute Behavioral and Electrophysiological Effects of Bupropion (Wellbutrin®) Are Mediated by a Noradrenergic Mechanism
TLDR
The results suggest that bupropion preferentially affects NE neurons in locus coeruleus at doses that are active in animal antidepressant tests, and require a reserpine-sensitive store of NE and occur at doses having activity in antidepressant screening tests.
Bupropion is a nicotinic antagonist.
TLDR
Bupropion was found to block nicotine's antinociception, motor effects, hypothermia, and convulsive effects with different potencies in the present investigation, suggesting that bupropion possesses some selectivity for neuronal nicotinic receptors underlying these various Nicotinic effects.
Noncompetitive functional inhibition at diverse, human nicotinic acetylcholine receptor subtypes by bupropion, phencyclidine, and ibogaine.
  • J. Fryer, R. Lukas
  • Biology
    The Journal of pharmacology and experimental therapeutics
  • 1999
TLDR
Functional blockade is insurmountable by increasing agonist concentrations in TE671/RD and SH-SY5Y cells for each of these drugs, suggesting noncompetitive inhibition of nAChR function and hypothesize that nA ChR are targets of diverse substances of abuse and agents used in antiaddiction/smoking cessation strategies.
Pharmacokinetics of Bupropion and its Metabolites in Cigarette Smokers versus Nonsmokers
TLDR
The absence of pharmacokinetic differences indicates that dosage adjustments are not necessary when bupropion is prescribed to male and female cigarette smokers.
Bupropion: a review of its mechanism of antidepressant activity.
TLDR
The mechanism of action of buPropion appears to have an unusual, not fully understood, noradrenergic link, and the mild central nervous system activating effects of bupropion appear to be due to weak dopaminergic mechanisms.
Studies of selected phenyltropanes at monoamine transporters.
Bupropion in depression. II. The role of metabolites in clinical outcome.
TLDR
The steady-state pharmacokinetics of bupropion hydrochloride, a unicyclic aminoketone antidepressant, in depressed patients and the metabolites hydroxybupropion, threohydrobupropions, and erythrohydrob upropion predominated over the parent compound in plasma and cerebrospinal fluid at steady state, with higher plasma metabolite concentrations associated with poor clinical outcome.
Pharmacological significance of the species differences in bupropion metabolism.
TLDR
Mice, dogs and man form a major side chain hydroxylated product (BW 306U) which appeared in higher concentration than bupropion in plasma of these species but not rats, which may account for the species difference in pharmacological response observed with bupropions.
...
...